Comparative Pharmacology
Head-to-head clinical analysis: ARICEPT versus ARICEPT ODT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARICEPT versus ARICEPT ODT.
ARICEPT vs ARICEPT ODT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible inhibitor of acetylcholinesterase, increasing acetylcholine levels in the synaptic cleft of the central nervous system.
Reversible acetylcholinesterase inhibitor, increasing acetylcholine concentration in the synaptic cleft of central cholinergic neurons.
Initial: 5 mg orally once daily for 4-6 weeks; may increase to 10 mg once daily. Maximum: 10 mg per day. Route: oral. Frequency: once daily.
5 mg orally once daily; may increase to 10 mg once daily after 4-6 weeks.
None Documented
None Documented
70 hours (terminal elimination half-life; steady-state reached in 15-21 days; once-daily dosing appropriate)
Terminal elimination half-life: 70 hours (range 50-80 hours). Clinical context: Steady-state achieved in 15-21 days; once-daily dosing maintains therapeutic concentrations.
Renal (57% unchanged drug, 17% as metabolites), fecal (30%), biliary (minimal)
Renal: 57% (as unchanged drug and metabolites); Fecal: 15%; Biliary: minor
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor